Saturday, Apr 20 2024 | Time 02:55 Hrs(IST)
image
Business EconomyPosted at: Jan 17 2023 4:40PM


MSN Group launches Palbociclib tablets for advanced breast cancer therapy

Hyderabad, Jan 17 (UNI) MSN Group, one of the fastest-growing, research-based fully integrated pharmaceutical companies, on Tuesday announced the launch of the world’s first generic Palbociclib 75 mg, 100 mg and 125 mg tablets for Advanced Breast Cancer Therapy under the brand name 'Palborest'.
While there are few other companies launched/set to launch Palbociclib in capsule dosage form, the Hyderabad based MSN laboratories took the lead in developing the drug in tablet formulation which is in line with the innovator Palbace®tablets.
Priced at Rs 257.14 per tablet for 125 mg, Rs 233.28 per tablet for 100 mg, Rs 214.29 per tablet for 75 mg respectively, Palborest is more affordable & bioequivalent to innovator tablet, the pharmaceutical company said in a release.
The tablet dosage form offers distinct advantage over capsule dosage form as they can be taken with or without food. These tablets can be co-administered with Proton Pump Inhibitors (PPIs) or antacids.
The tablet formulation does not contain lactose (dairy) or gelatin, which also contributes to the efficacy of the drug.
Palborest comes in a patient compliant pack of 3 strips of 7 tablets each to meet the recommended 3-weeks on, 1-week off treatment schedule.
Palbociclib is approved by the USFDA, EMA and CDSCO in combination with hormonal therapies for patients with hormone receptor positive, human epidermal growth factor, receptor negative locally advanced or metastatic breast cancer.
MSN Group commented, “We at MSN Group have continuing commitment to research and develop affordable oncology drugs for better adherence, treatment outcomes and minimizing the economic burden on patients.”
The product wholly developed and manufactured in-house, from API to Formulation, in USFDA/EU approved facilities, allows MSN Group to ensure seamless access to quality medicine at economical costs.
The company presently has 21 state-of-the-art manufacturing facilities (fifteen API and six finished dosage facilities) in India and USA.
UNI KNR CS1640
Please log in to get detailed story.
Tags: #MSN Group launches Palbociclib tablets for advanced breast cancer therapy
More News

"CSIR-IICT and BHEL partners to advance clean fuel technology: MoU signed on CO2 to DME"

19 Apr 2024 | 7:23 PM

Hyderabad, April 19 (UNI) The Council of Scientific and Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT) and Bharat Heavy Electricals Limited (BHEL) Corporate R&D have forged a partnership to develop technology for capturing and converting carbon dioxide (CO2) to Dimethyl Ether (DME) through direct catalytic conversion.

see more..

Amara Raja Infra Wins Greenko’s 700MWp solar project in AP

19 Apr 2024 | 6:41 PM

Hyderabad, Apr 19 (UNI) Amara Raja Infra Private Limited (ARIPL), part of the $1.75 billion Amara Raja Group, on Friday announced it has secured a solar BoS (Balance of System) project of 500MW/700MWp from Greenko.

see more..
Sensex recovers 600 points on heavy buying on last day of week

Sensex recovers 600 points on heavy buying on last day of week

19 Apr 2024 | 5:34 PM

Mumbai, April 19 (UNI) Snapping a losing streak of last four sessions, the BSE Sensex on Friday bounced back 599.34 points to close at 73088.33 on expectation of minimal escalation of tension between Israel and Iran.

see more..

19 Apr 2024 | 5:24 PM

Mumbai, Apr 19 (UNI) IT major Wipro on Friday reported 7.80% year-on-year dip in consolidated net profit at Rs 2,834.6 crore for January-March quarter (Q4) of the financial year 2023-24.

see more..
Rupee up 8 paise against USD

Rupee up 8 paise against USD

19 Apr 2024 | 5:05 PM

Mumbai, April 19 (UNI) The Rupee on Friday ended positive at 83.47, rising 8 paise against the USD on selling US Dollar by bankers and exporters, dealers at the Foreign exchange said.

see more..
image